Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Stock Swap -- Ignore unavailable to you. Want to Upgrade?

To: Andrew Vance who wrote (16892)	12/20/1999 4:24:00 PM
From: Tech Master	Read Replies (1) \| Respond to of 17305

Monday December 20, 3:52 pm Eastern Time Company Press Release Initial Patients Treated in Phase I Clinical Studies of Celsion's Breast Cancer and Benign Prostatic Hyperplasia Systems A Product Development Update COLUMBIA, Md.--(BW HealthWire)--Dec. 20, 1999--Celsion Corporation (OTC BB:CELN) today announced that initial patients have been treated in both the Phase I clinical studies for its breast cancer treatment system and its expanded Phase I clinical studies for its benign prostatic hyperplasia (BPH) system. Phase I clinical trials are designed to evaluate the feasibility and safety of these systems in patients. The Company's breast cancer treatment system is designed to destroy cancerous tumors using heat alone. Phase I clinical studies for Celsion's system began this December at The Center for Breast Surgery (a Columbia/HCA affiliate) in West Palm Beach, FL and are expected to begin at Harbor Medical Center in Los Angeles, CA later this month. A total of 10 patients are planned for this Phase I study. It is intended that the Company's treatment system will provide a non-surgical, minimally invasive treatment for breast cancer that is non-toxic and side effect free. The Company's BPH treatment system utilizes a proprietary microwave balloon catheter designed to treat enlarged prostates, a condition that affects older men. After completing Phase I clinical studies of the system earlier this year, the Company was granted approval from the U.S. Food ad Drug Administration (FDA) to conduct an expanded Phase I study with revised protocol that is designed to shorten the treatment time and simplify its software requirements. The Company stated that the expanded Phase I BPH clinicals began earlier this month at Montefiore Medical Center in New York, NY. A total of 10 patients are planned for this expanded study. Celsion said that it plans to apply to the FDA for approval to conduct Phase II clinical trials if its Phase I breast cancer and BPH results are successful. Phase II trials evaluate the efficacy of treatment systems. The Company stated that if the Phase II clinicals prove successful, application would be made to the FDA for PreMarket Approval (PMA) to allow commercialization of the systems in the USA. ``We are pleased with the progress that Celsion has made this year, which is a tribute to the hard work of everyone involved. We look forward to continuing opportunities for the Company in the year 2000,' said Spencer J. Volk, chief executive officer and president of Celsion. Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and benign prostatic hyperplasia using focused heat delivered by patented microwave technology. Clinicals and further development of the Company's treatment systems are being conducted by leading institutions such as the Columbia Hospital (a Columbia/HCA Healthcare member), Duke University, Harbor UCLA Medical Center, Massachusetts Institute of Technology, Montefiore Medical Center and UCSF. Forward-looking statements in this release are made pursuant to the ``safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, possible changes in cost of materials, expense items, capital expenditures, capital structure, and other financial items; introduction of new products and possible acquisitions of assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.